MiRNA as a Potential Target for Multiple Myeloma Therapy-Current Knowledge and Perspectives

Area of Science:

• Hematological Malignancies
• Molecular Biology
• Cancer Research

Background:

• Multiple myeloma (MM) is a prevalent hematological malignancy with limited curative options despite therapeutic advancements.
• MicroRNAs (miRNAs), small non-coding RNAs regulating gene expression, are frequently dysregulated in MM.
• miRNAs can function as oncogenes or tumor suppressors in MM pathogenesis.

Purpose of the Study:

• To review the role of miRNAs in multiple myeloma development.
• To summarize the current status of miRNA-based therapies in preclinical and clinical trials for MM.
• To explore the theoretical mechanisms of therapeutic benefit from miRNA modulation in MM.

Main Methods:

• Literature review of studies on miRNA function and therapeutic potential in multiple myeloma.
• Analysis of preclinical and clinical trial data for miRNA-based anti-myeloma strategies.
• Discussion of molecular mechanisms underlying miRNA-mediated gene regulation in MM.

Main Results:

• Aberrant miRNA expression is a hallmark of multiple myeloma.
• miRNA mimics and antagomirs demonstrate potential to restore normal gene regulatory networks in MM.
• While promising, few miRNA-based drugs have advanced to clinical trials for MM.

Conclusions:

• MicroRNAs represent a promising class of targets for novel anti-myeloma therapies.
• Modulating miRNA expression offers a potential strategy to normalize signaling pathways in MM cells and the microenvironment.
• Further clinical investigation of miRNA-based therapeutics is warranted for effective MM treatment.